Inc.announced topline results from theMOVE-FA study of vatiquinonein Friedreich ataxia patients. The primary goal of statistically significant change in mFARS score at 72 weeks was not met in the primary analysis population. Thevatiquinone treatment for Friedreich ataxia, on the other hand, demonstr...